Beam Therapeutics is a United States biotechnology company developing precision genetic medicines using base editing technology. Base editing aims to make targeted changes to DNA without relying on the same double stranded cutting mechanism used by some other gene editing approaches. Its development work includes serious inherited diseases, including conditions affecting blood and liver metabolism. Founded in 2017, Beam has its headquarters in Cambridge, Massachusetts, and manufacturing operations in North Carolina. The company publishes official investor disclosures and clinical updates through its website.
Cambridge, MassachusettsSelf-reported location on the company LinkedIn page; regional scope may differ from the legal or global headquarters.Sources (1)
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Beam Therapeutics is a United States biotechnology company developing precision genetic medicines using base editing technology. Base editing aims to make targeted changes to DNA without relying on the same double stranded cutting mechanism used by some other gene editing approaches. Its development work includes serious inherited diseases, including conditions affecting blood and liver metabolism. Founded in 2017, Beam has its headquarters in Cambridge, Massachusetts, and manufacturing operations in North Carolina. The company publishes official investor disclosures and clinical updates through its website.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Beam develops investigational precision genetic medicines using base editing. Its website describes a delivery strategy spanning electroporation and nonviral and viral approaches. Those routes include different applications; the platform label alone does not establish in vivo efficacy.
Business, technology & evidence
Beam Therapeutics is a United States biotechnology company developing precision genetic medicines using base editing technology. Base editing aims to make targeted changes to DNA without relying on the same double stranded cutting mechanism used by some other gene editing approaches. Its development work includes serious inherited diseases, including conditions affecting blood and liver metabolism. Founded in 2017, Beam has its headquarters in Cambridge, Massachusetts, and manufacturing operations in North Carolina. The company publishes official investor disclosures and clinical updates through its website.
SecuritiesNasdaq Global Select Market: BEAM
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Beam presented updated open-label Phase 1/2 data for BEAM-302, an LNP-delivered in vivo base-editing treatment for alpha-1 antitrypsin deficiency. Follow-up extended to 18 months after one dose, with increased functional AAT and reduced mutant Z-AAT and circulating polymers. Dosing is underway in a pivotal cohort. These biomarker findings do not yet establish controlled evidence of improved lung or liver clinical outcomes.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
